UPC Analytics
ENDE
Analytics1Cases1Decisions3Judges2Parties0Firms
Filing trendsOutcomesPendencyTechnologyForum strategyLeading casesLegal issuesSecurity for costs

Legal issues

Cross-cutting view of legal principles, recurring arguments, and the prior art the court relies on.

Legal principlecosts follow the event under Art. 69 UPCA and Art. 14 Directive 2004/48Clear all

Filtering to principle: costs follow the event under Art. 69 UPCA and Art. 14 Directive 2004/48

Clear principle filter
Most-litigated legal principles
Recurring legal principles across 1 cases with reasoning extracted. Success rate counts patentee-favorable outcomes only.
PrincipleCasesDecidedPatentee success
imminent infringement must arise directly from conduct of potential infringer110%
pharmaceutical regulatory steps (marketing authorisation, pep request) do not per se establish imminent infringement110%
costs follow the event under art. 69 upca and art. 14 directive 2004/48110%
Most-rejected arguments
Arguments that the UPC has not accepted, ranked by repeat occurrences across cases.
ArgumentPartyCases
imminent infringement established by infarmed notice, receipt of marketing authorisations, and filing of pep requestClaimant1
Most-cited prior art
References relied on across substantive merits cases, with the role they typically play.

No prior-art data in the current scope.